#United Kingdom #CPI #Nottingham #RNA Therapy #Quotient Sciences

Quotient Sciences and CPI Launch Joint Venture to Accelerate RNA Drug Development

In a significant move to expedite the development of RNA-based therapies, Quotient Sciences, a recognized leader in drug manufacturing, has partnered with CPI, a UK-based technology innovation center. This collaboration, formalized through a memorandum of understanding (MoU), aims to create a joint venture (JV) that amalgamates their expertise and technological capabilities to address the growing needs of RNA drug development.

The joint venture seeks to integrate Quotient Sciences' Translational Pharmaceutics® platform with CPI's specialized skills in small-scale production of RNA and lipid nanoparticles (LNP) encapsulation. This alliance promises a novel approach to developing mRNA drug products, ultimately enabling a more efficient and streamlined process that can bring crucial RNA therapies to patients faster and with greater reliability.

Thierry Van Nieuwenhove, CEO of Quotient Sciences, expressed that this JV represents a crucial evolution in RNA drug development. He noted, “The combined innovation and deep technical expertise of Quotient and CPI will enable developers to benefit from a vastly accelerated supply chain, with clinical batches going from plasmid to clinical dose in as little as two months.” This streamlined process not only promises to shorten the overall timeline but also enhances the likelihood of success during early-phase clinical trials.

The joint venture will encompass various stages of RNA drug development, including:

• - mRNA synthesis
• - LNP formulation development
• - Clinical manufacturing
• - Early-phase clinical testing

By bringing these stages under one umbrella, this collaboration allows rapid transitions from DNA to RNA and subsequently into clinical trials, effectively reducing the time and increasing the potential for success based on real-time clinical data collected from healthy volunteers.

Frank Millar, CEO of CPI, highlighted the importance of this partnership, stating, “We’re proud to be partnering with Quotient Sciences on this initiative that represents a bold step forward for the RNA ecosystem. Our shared vision is to enable scalable and sustainable development pathways for mRNA therapies that meet global health challenges head-on.”

Quotient Sciences is well-known for applying its Translational Pharmaceutics® approach globally, having successfully supported over 500 programs for both biotechnology and larger pharmaceutical clients involving various drug candidates, including small molecules and peptides. The new JV extends this approach to RNA-based therapeutic areas, highlighting the growing importance and demand for RNA therapies in the medical field.

As the partnership progresses, further details regarding the name, branding, and operational roadmap of the joint venture will be shared, signifying exciting developments on the horizon for RNA therapeutics.

About Quotient Sciences

Quotient Sciences is a drug development and manufacturing accelerator that provides integrated programs and tailored services across the entire development pathway. By bridging multiple drug development capabilities, they allow for a faster and more efficient process in bringing drugs to market. Their dedication to transforming ideas into actionable solutions has been recognized by multiple accolades, including the CRO Leadership Awards and CDMO Leadership Awards.

About CPI

CPI operates as an independent technology innovation center and is a founding member of the UK Government's High Value Manufacturing Catapult. Since its inception in 2004, CPI has played a pivotal role in supporting organizations in bringing innovative ideas to market, reducing the associated risks and costs tied to research and development. They strive to work collaboratively with partners across various sectors to facilitate the advancement of next-generation medicines and technologies.